RE:Pharma companies should be lining up to partner with usI think the only thing between PMN and that multi-billion dollar valuation is a big partner or a funded PhI. A big partner would be better long term, especially if it involved future revenue splits instead of just ownership.
I still think Zack's small cap analyst John Vandermosten's valuation of $5 per share was pretty reasonable given the market size and strong technical case for PMN310.
And now the FDA has blessed the amyloid beta approach, even acknowledging that their approval was more based on the mechanism than the data. And I agree with their approach here. Build the infrastructure and market. BAN2401 and PMN 310 are worth the investment in aducanumab.